Active Filter(s):
Details:
IsoTherapeutics will modify Monopar’s proprietary uPAR targeted antibody, MNPR-101, by making conjugates that will attachment of therapeutic radioisotopes supplied by NorthStar, creating a platform of uPAR-targeted RIT candidates to be studied to treat severe COVID-19.
Lead Product(s): MNPR-101
Therapeutic Area: Infections and Infectious Diseases Product Name: MNPR-101
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: NorthStar Medical Radioisotopes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 10, 2020